Sculier D, Wandeler G, Yerly S, Marinosci A, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. PLoS Med 2020;17:e1003421.
PMID: 33170863